{"pmid":32221153,"title":"The looming pandemic of COVID-19: What therapeutic options do we have now?","text":["The looming pandemic of COVID-19: What therapeutic options do we have now?","J Chin Med Assoc","Afsar, Nasir Ali","32221153"],"journal":"J Chin Med Assoc","authors":["Afsar, Nasir Ali"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221153","week":"202014|Mar 30 - Apr 05","doi":"10.1097/JCMA.0000000000000310","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662624089112576000,"score":7.2532344,"similar":[{"pmid":32180224,"title":"How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?","text":["How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?","Br J Haematol","Dholaria, Bhagirathbhai","Savani, Bipin N","32180224"],"journal":"Br J Haematol","authors":["Dholaria, Bhagirathbhai","Savani, Bipin N"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32180224","week":"202012|Mar 16 - Mar 22","doi":"10.1111/bjh.16597","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543559917569,"score":45.13442},{"pmid":32108093,"title":"Strategies shift as coronavirus pandemic looms.","text":["Strategies shift as coronavirus pandemic looms.","Science","Cohen, Jon","Kupferschmidt, Kai","32108093"],"journal":"Science","authors":["Cohen, Jon","Kupferschmidt, Kai"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108093","week":"20209|Feb 24 - Mar 01","doi":"10.1126/science.367.6481.962","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1662334544212131841,"score":44.422966},{"pmid":32145386,"title":"Remdesivir as a possible therapeutic option for the COVID-19.","text":["Remdesivir as a possible therapeutic option for the COVID-19.","Travel Med Infect Dis","Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A","32145386"],"journal":"Travel Med Infect Dis","authors":["Al-Tawfiq, Jaffar A","Al-Homoud, Ali H","Memish, Ziad A"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32145386","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.tmaid.2020.101615","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543919579137,"score":42.84197},{"pmid":32127666,"title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","text":["Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","Nat Rev Drug Discov","Li, Guangdi","De Clercq, Erik","32127666"],"journal":"Nat Rev Drug Discov","authors":["Li, Guangdi","De Clercq, Erik"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127666","week":"202010|Mar 02 - Mar 08","doi":"10.1038/d41573-020-00016-0","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1662334544030728192,"score":41.043076},{"pmid":31996494,"title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV).","text":["Drug treatment options for the 2019-new coronavirus (2019-nCoV).","As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.","Biosci Trends","Lu, Hongzhou","31996494"],"abstract":["As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments."],"journal":"Biosci Trends","authors":["Lu, Hongzhou"],"date":"2020-01-31T11:00:00Z","year":2020,"_id":"31996494","week":"20205|Jan 27 - Feb 02","doi":"10.5582/bst.2020.01020","keywords":["2019-nCoV","Coronaviruses","pneumonia"],"source":"PubMed","locations":["China","Chinese","Capsules"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544669310976,"score":41.043076}]}